Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
panobinostat + trastuzumab + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (panobinostat), Intravenous (panobinostat, Trastuzumab, Paclitaxel)
01
Overview
Panobinostat + trastuzumab + paclitaxel is an investigational drug combination evaluated for the treatment of HER2-positive metastatic breast cancer. Panobinostat is a small molecule histone deacetylase inhibitor (HDAC inhibitor) that disrupts transcriptional processes leading to apoptosis and cell cycle arrest. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and mediates its antitumor effects through blockade of HER2 signaling, antibody-dependent cellular cytotoxicity, and inhibition of HER2-mediated cell proliferation. Paclitaxel is an antineoplastic small molecule that stabilizes microtubules, resulting in inhibition of mitosis and cell division. The combination is being studied for synergistic antitumor effects in HER2+ breast cancer, aiming to overcome resistance and improve clinical outcomes[1][2][3][5][7][10].
- Brand names
- Taxol (for paclitaxel)Herceptin (for trastuzumab)
- Other names
- panobinostat + trastuzumab + paclitaxel
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)HDAC (HDAC family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on panobinostat + trastuzumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on panobinostat + trastuzumab + paclitaxel.